iShares Biotechnology ETF
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
10% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 73
0% less funds holding
Funds holding: 879 [Q2] → 876 (-3) [Q3]
9% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 10 (-1) [Q3]
12% less capital invested
Capital invested by funds: $5.94B [Q2] → $5.23B (-$702M) [Q3]
12.52% less ownership
Funds ownership: 79.69% [Q2] → 67.17% (-12.52%) [Q3]
24% less repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 315
39% less call options, than puts
Call options by funds: $496M | Put options by funds: $810M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 8 articles about IBB published over the past 30 days
Neutral
CNBC Television
1 day ago
How tariffs could impact pharma and early-stage healthcare investments
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
Positive
ETF Trends
1 day ago
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Neutral
Zacks Investment Research
1 day ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Negative
Yahoo Finance
5 days ago
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.
Negative
24/7 Wall Street
1 week ago
I Was Convinced Biotech Stocks Were Too Risky—This Innovation's Changing the Game
The biotech scene can be seen as fairly risky for new investors who want to put money to work.
Neutral
See It Market
2 weeks ago
Important Stock Market ETFs Begin January Trend Trade
For today's market update, I am giving you a peek at our all-important list of stock market ETFs and where they all sit relative to this significant trading range reset. If you are unfamiliar with the January Calendar range, the Outlook 2025, link further below, covers a brief description.
Positive
Seeking Alpha
3 weeks ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Negative
See It Market
3 weeks ago
Stock Market Sell-Off? Key ETFs Holding Up
I have read so many scary headlines this week. And let's face it, the stock market sell-off, especially in quantum computer stocks, is sobering.
Neutral
See It Market
1 month ago
Key Stock Market ETFs Start 2025 With Cautious Patterns
I hope everyone had a wonderful holiday and has a very happy and successful New Year. I spent time with my family and of course watched the key stock market etfs carefully.
Positive
See It Market
1 month ago
Why Biotech Sector ETF (IBB) May Turn Bullish In 2025
One of the big themes we see emerging into 2025 is an expansion in Biotechnology and a bullish backdrop for certain biotechnology stocks.
Charts implemented using Lightweight Charts™